Bimekizumab for treating moderate to severe hidradenitis suppurativa (terminated appraisal)

  • Technology appraisal
  • TA1028
  • Published: 

History

Draft guidance: 1

Invitation to participate

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators